Etranacogene Dezaparvovec

Etranacogene dezaparvovec conferred superior bleed control for adults with moderate or severe hemophilia B compared with standard factor IX prophylaxis, according to results of the phase 3 HOPE-B study.

The gene therapy etranacogene dezaparvovec conferred a substantial decrease in bleeding events among patients with moderate or severe hemophilia B, according to preliminary data presented at the virtual ASH Annual Meeting and Exposition.